Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | 英语 |
出版: |
2018
|
在線閱讀: | https://doi.org/10.1186/s12931-018-0957-y https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|